What Generation of Cephalosporin Is Ceftazidime?

Ceftazidime is a third-generation cephalosporin, a class of antibiotics that emerged in the early 1980s with broader activity against gram-negative bacteria than the generations before them.¹ Within that third-generation group, though, ceftazidime has a specific reputation: it is unusually potent against Pseudomonas aeruginosa, a notoriously hard-to-kill bacterium that causes serious hospital-acquired infections.² That anti-Pseudomonas strength is the trait that defines ceftazidime’s clinical niche and explains why it gets treated differently from other drugs in the same generation.

What “Third Generation” Actually Means

Cephalosporins are grouped into generations based on when they were developed and, more practically, on their spectrum of activity. First-generation drugs work well against common gram-positive bacteria like staphylococci and streptococci but have limited reach against gram-negative organisms. Second-generation drugs expanded gram-negative coverage somewhat. Third-generation cephalosporins, including ceftazidime, ceftriaxone, and cefotaxime, pushed that gram-negative activity much further, covering a wide range of Enterobacteriaceae while also resisting breakdown by many of the beta-lactamase enzymes that bacteria use to neutralize older antibiotics.³

The trade-off for this broader gram-negative punch was generally weaker activity against some gram-positive organisms compared to first-generation drugs. That gram-positive weakness is more pronounced in ceftazidime than in its third-generation siblings, which becomes important when choosing between them in clinical practice.

Why Ceftazidime Stands Apart from Other Third-Generation Drugs

Not all third-generation cephalosporins are interchangeable. Ceftriaxone and cefotaxime, the two other workhorses in this generation, are the go-to choices for gram-negative infections where Pseudomonas is not a concern. They cover a wide range of Enterobacteriaceae and have solid activity against Streptococcus pneumoniae, the bacterium behind many cases of pneumonia and meningitis. Ceftazidime, by contrast, is roughly eight to sixteen times less active against S. pneumoniae than cefotaxime or ceftriaxone, meaning it only reliably covers strains that are already susceptible to penicillin.⁴

Where ceftazidime earns its place is against Pseudomonas aeruginosa. In laboratory testing, it proved to be the most active agent tested against Pseudomonas, with a very low concentration needed to stop growth. It even inhibited Pseudomonas strains that had already become resistant to other anti-Pseudomonal drugs like carbenicillin and piperacillin.⁵ This is why drug utilization reviews have recommended that ceftazidime be reserved primarily for Pseudomonas infections where other agents are not suitable, while cefotaxime and ceftriaxone handle other serious gram-negative infections where Pseudomonas can be ruled out.⁶

Another practical difference: ceftriaxone has a notably long half-life and can be eliminated through two routes in the body, which allows once-daily dosing. Ceftazidime typically requires dosing every eight hours.⁷

How Ceftazidime Kills Bacteria

Like all cephalosporins and penicillins, ceftazidime belongs to the beta-lactam family. These drugs work by binding to penicillin-binding proteins (PBPs), which are enzymes bacteria need to build and maintain their cell walls. When those enzymes are blocked, the bacterium can no longer sustain its wall structure, and the cell eventually bursts.

Ceftazidime’s primary target is PBP-3, which is involved in cell division. When the drug locks onto PBP-3 in E. coli and Pseudomonas aeruginosa, bacteria start elongating into long filaments instead of dividing normally, and eventually lyse. At somewhat higher concentrations that are still achievable during therapy, ceftazidime also hits PBP-1a and PBP-1b, proteins critical for cell elongation. Blocking these additional targets accelerates cell death.⁸

Beta-Lactamase Resistance and Its Limits

One of the selling points of third-generation cephalosporins, including ceftazidime, is their stability against many beta-lactamases. Bacteria produce these enzymes specifically to chew up beta-lactam antibiotics before they can reach their PBP targets. Ceftazidime’s molecular structure makes it resistant to hydrolysis by most common beta-lactamases. Crystallography work has shown that ceftazidime physically cannot adopt the shape needed for certain beta-lactamase enzymes to break it apart efficiently, because parts of the drug molecule clash with conserved amino acids in the enzyme’s active site.⁹

That said, bacteria have found workarounds. AmpC beta-lactamases, a class of enzymes commonly produced by Enterobacter species, can be overexpressed during therapy. When that happens, an infection that initially appeared susceptible to ceftazidime can become resistant while the patient is being treated. This is a well-documented problem with Enterobacter aerogenes and Enterobacter cloacae and represents one of the most clinically frustrating scenarios for clinicians relying on third-generation cephalosporins.¹⁰

Extended-spectrum beta-lactamases (ESBLs), which emerged in part because of widespread cephalosporin use, can also break down ceftazidime. And carbapenemases, the most alarming of these enzymes, confer resistance to nearly all beta-lactams. The ongoing evolution of these resistance mechanisms is what drove the development of newer drug combinations designed to protect ceftazidime’s effectiveness.

The Avibactam Partnership

Ceftazidime-avibactam, approved in 2015, pairs ceftazidime with a non-beta-lactam beta-lactamase inhibitor that can neutralize many of the enzymes that had rendered ceftazidime useless. Avibactam covers Class A (including many ESBLs and KPC carbapenemases), Class C (AmpC), and some Class D beta-lactamases. In testing against carbapenem-resistant Enterobacterales, adding avibactam restored ceftazidime’s activity in nearly all isolates tested.¹¹

When compared head-to-head against other recent beta-lactam/inhibitor combinations, ceftazidime-avibactam performed strongly. Against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals, it inhibited every isolate tested, while the competing combinations meropenem-vaborbactam and imipenem-relebactam each inhibited around 93% of isolates.¹² This combination essentially gave ceftazidime a second life against organisms that had evolved well past the third-generation drugs’ original reach.

One gap worth noting: avibactam does not inhibit Class B metallo-beta-lactamases, which are the predominant carbapenemase type in some regions. Against bacteria carrying those enzymes, ceftazidime-avibactam is still ineffective, and other strategies are needed.

How the Body Handles Ceftazidime

Ceftazidime is given intravenously or intramuscularly; it is not absorbed well enough from the gut to be taken by mouth. In healthy people, it distributes through body fluids reasonably well and is eliminated primarily by the kidneys, with a half-life of about two hours. In critically ill patients, though, the pharmacokinetics shift substantially. The volume of distribution can roughly double, and the half-life can climb to nearly five hours, because critical illness causes fluid shifts, altered blood flow, and changes in kidney function.¹³

This matters because ceftazidime’s effectiveness depends on maintaining drug levels above the minimum inhibitory concentration for a sufficient fraction of the dosing interval. When the volume of distribution increases, the initial peak concentration can be lower than expected, and the drug spends more time at sub-therapeutic levels despite the longer half-life. For this reason, extended or continuous infusion strategies have become increasingly popular in intensive care settings, aiming to keep drug levels more consistently above the needed threshold.

Neurotoxicity Risk in Kidney Impairment

Because ceftazidime clears through the kidneys, reduced renal function can lead to drug accumulation and serious side effects. The most concerning is neurotoxicity, which can present as confusion, progressive loss of consciousness, and myoclonic seizures. A review of reported cases found that most patients who developed ceftazidime-related neurotoxicity had some form of kidney impairment, and that the drug had not been appropriately dose-reduced for their renal function. Analysis of reported drug levels suggested that neurotoxicity risk rises sharply once blood concentrations exceed about 78 mg/L.¹⁴

The good news is that symptoms typically improve within days after stopping the drug. But prevention is better than rescue: dose adjustment based on kidney function is not optional. This is equally true in children, where modeling work has shown that drug exposure can be two to six times higher than expected if standard doses are given to children with moderate to end-stage kidney disease. Those studies have suggested specific reduced doses scaled to the severity of renal impairment to keep drug exposure within the effective range without crossing into toxic territory.¹⁵

Therapeutic Drug Monitoring

Given the pharmacokinetic variability in sick patients and the real risk of neurotoxicity when levels get too high, there has been growing interest in monitoring ceftazidime blood levels directly rather than relying solely on calculated dose adjustments. This is especially relevant for critically ill patients on continuous kidney-replacement therapies, where drug removal can be unpredictable. A case report of a child receiving ceftazidime-avibactam while on continuous dialysis found that drug clearance was higher than expected from adult data, raising the risk of treatment failure and resistance development.¹⁶ Situations like these illustrate why some centers are moving toward routine drug-level monitoring for beta-lactams in the ICU, a practice that was once considered unnecessary for this class of antibiotics.

Where Ceftazidime Fits in Modern Practice

Ceftazidime’s role has narrowed since its heyday in the 1980s and 1990s. It remains important for confirmed or strongly suspected Pseudomonas infections, particularly in settings like hospital-acquired pneumonia, complicated urinary tract infections, and bloodstream infections in immunocompromised patients. Surveillance data from Germany showed an overall ceftazidime resistance proportion of about 6.7% in human E. coli isolates in 2020, with a declining trend, suggesting that resistance levels for this drug are at least not spiraling upward in all settings.¹⁷

However, guidelines from major infectious disease societies have backed away from recommending ceftazidime as a first-line empiric choice for febrile neutropenia, where it was once a standard option. Updates suggest that broader-spectrum agents may be more appropriate in many institutional settings, reflecting the increasing prevalence of resistant organisms that ceftazidime alone cannot reliably cover.¹⁸ Where ceftazidime has regained relevance is in its combination with avibactam, which has become a frontline therapy for infections caused by many carbapenem-resistant organisms.

Cephalosporin Resistance in Animals

Third-generation cephalosporin resistance is not confined to human medicine. In companion animals, cephalosporins closely related to ceftazidime are used for infections like abscesses, bite wounds, and urinary tract infections. Cefovecin, a long-acting veterinary cephalosporin given by injection, is popular in cats partly because a single dose lasts about two weeks, which avoids the stress and compliance issues of owners giving pills to a cat at home.¹⁹

The concern is that cephalosporin use in animals selects for resistant E. coli and other bacteria that can potentially transfer resistance genes to human pathogens. Surveillance studies tracking resistance in pets have found third-generation cephalosporin-resistant E. coli in both dogs and cats, and the overlap between the resistance genes found in animal and human isolates keeps this a live question in public health. Hospital wastewater has also been identified as a potential selective environment, with evidence that effluent containing antibiotic residues can favor the survival of ceftazidime-resistant bacterial strains.²⁰ The selective pressure does not require high antibiotic concentrations; even the low levels found in wastewater influent can nudge the bacterial population toward resistant strains over time.